{
    "ticker": "BTBDW",
    "name": "Better Therapeutics, Inc.",
    "description": "Better Therapeutics, Inc. is an innovative biotechnology company focused on developing prescription digital therapeutics to treat cardiometabolic diseases. Founded in 2015, Better Therapeutics combines behavioral science and digital technology to create personalized, engaging therapies that empower patients to manage their health and improve their outcomes. The company's flagship product is a digital therapeutic designed for the treatment of type 2 diabetes, which utilizes cognitive behavioral therapy principles to engage users in self-management strategies. This approach not only addresses the clinical symptoms of diabetes but also targets the underlying behavioral factors contributing to the disease. Better Therapeutics' platform is built on a foundation of clinical evidence and is designed to be easily integrated into existing healthcare systems, providing physicians with tools to offer new treatment options for their patients. The company aims to revolutionize the way chronic diseases are managed, moving from traditional medication-based approaches to more holistic, patient-centered treatments. With a strong pipeline of products in development, Better Therapeutics is committed to advancing the field of digital health and improving patient outcomes through innovative therapeutic solutions.",
    "industry": [
        "Biotechnology",
        "Digital Health"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.bettertx.com",
    "ceo": "Kevin O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/BetterTherapeutics",
        "linkedin": "https://www.linkedin.com/company/better-therapeutics/"
    },
    "investor_relations": "https://ir.bettertx.com",
    "key_executives": [
        {
            "name": "Kevin O'Connor",
            "position": "CEO"
        },
        {
            "name": "Derek D. Rapp",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Digital Therapeutics",
            "products": [
                "BT-001 (for Type 2 Diabetes)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Better Therapeutics, Inc. | Prescription Digital Therapeutics",
        "meta_description": "Explore Better Therapeutics, Inc., a leader in prescription digital therapeutics for cardiometabolic diseases. Discover how our innovative approaches are transforming chronic disease management.",
        "keywords": [
            "Better Therapeutics",
            "Digital Health",
            "Chronic Disease Management",
            "Type 2 Diabetes",
            "Prescription Digital Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Better Therapeutics focus on?",
            "answer": "Better Therapeutics focuses on developing digital therapeutics for the treatment of cardiometabolic diseases, particularly type 2 diabetes."
        },
        {
            "question": "Who is the CEO of Better Therapeutics?",
            "answer": "Kevin O'Connor is the CEO of Better Therapeutics, Inc."
        },
        {
            "question": "Where is Better Therapeutics headquartered?",
            "answer": "Better Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What is Better Therapeutics' main product?",
            "answer": "The main product is BT-001, a digital therapeutic designed for the treatment of type 2 diabetes."
        },
        {
            "question": "When was Better Therapeutics founded?",
            "answer": "Better Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "NVCR",
        "MZOR",
        "ABT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}